J
Joel C. Barrish
Researcher at Bristol-Myers Squibb
Publications - 209
Citations - 7119
Joel C. Barrish is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Protease & In vivo. The author has an hindex of 42, co-authored 207 publications receiving 6720 citations. Previous affiliations of Joel C. Barrish include Princeton University & Hoffmann-La Roche.
Papers
More filters
Journal ArticleDOI
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
Louis J. Lombardo,Francis Y. Lee,Ping Chen,Derek J. Norris,Joel C. Barrish,Kamelia Behnia,Stephen Castaneda,Cornelius Lyndon A M,Jagabandhu Das,Arthur M. Doweyko,Craig Fairchild,John T. Hunt,Ivan Inigo,Kathy A. Johnston,Amrita Kamath,David Kan,Herbert E. Klei,Punit Marathe,Suhong Pang,Russell Peterson,Sidney Pitt,Gary L. Schieven,Robert J. Schmidt,John S. Tokarski,Mei-Li Wen,John Wityak,Robert M. Borzilleri +26 more
TL;DR: Compound 13 was orally active in a K562 xenograft model of chronic myelogenous leukemia (CML), demonstrating complete tumor regressions and low toxicity at multiple dose levels.
Journal ArticleDOI
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor.
Jagabandhu Das,Ping Chen,Derek J. Norris,Ramesh Padmanabha,James Lin,Robert V. Moquin,Zhongqi Shen,Lynda S. Cook,Arthur M. Doweyko,Sidney Pitt,Suhong Pang,Ding Ren Shen,Qiong Fang,Henry F. De Fex,Kim W. McIntyre,David J. Shuster,Kathleen M. Gillooly,Kamelia Behnia,Gary L. Schieven,John Wityak,Joel C. Barrish +20 more
TL;DR: Molecular modeling was used to construct a putative binding model for Lck inhibition by Dasatinib and 12m, and the framework of key hydrogen-bond interactions proposed was in agreement with the subsequent, published crystal structure of 2 bound to structurally similar Abl kinase.
Patent
Cyclic protein tyrosine kinase inhibitors
Jagabandhu Das,Ramesh Padmanabha,Ping Chen,Derek J. Norris,Arthur M. Doweyko,Joel C. Barrish,John Wityak +6 more
TL;DR: In this paper, novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.
Patent
Isoxazolyl endothelin antagonists
TL;DR: The compounds N-[[2]-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxoxolyl)[1,1'-biphenyl]-2-yl]methyl]-N, 3, 3-trimethylbutanamide and N-(4, 5-dimethylamino-3)-isoxoxoxyl)-2-sulfonamide, and salts thereof, useful as endothelin antagonists as discussed by the authors.
Journal ArticleDOI
A new facile method for the synthesis of 1-arylimidazole-5-carboxylates
Bang-Chi Chen,Mark S. Bednarz,Rulin Zhao,Joseph E. Sundeen,Ping Chen,Zhongqi Shen,Amanda P. Skoumbourdis,Joel C. Barrish +7 more
TL;DR: In this paper, a new facile method for the preparation of 1-arylimidazole-5-carboxylates was developed, which involved reaction of anilines and ethyl glyoxylate in methanol to give α-anilino-α-methoxyacetates followed by cyclization with TosMIC.